评估CF和非CF支气管切开症患者的支气管扩展剂反应 - 一项随机对照研究
Mordechai Pollak1,2, Ronen Bar-Yoseph1,3, Moneera Hanna1
1Pediatric Pulmonary Institute, Rappaport Children's Hospital, Rambam Healthcare Campus, P.O. Box 9602, Haifa 3109601, Israel.
Journal of clinical medicine
|July 12, 2025
概括
支气管扩展剂反应 (BDR) 在支气管切除症患者中很少见. 虽然囊性纤维化 (CF) 和原发性纤维功能障碍 (PCD) 患者对萨尔布塔摩尔的反应比安慰剂更强,但其临床意义仍未确定.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 支气管切除症通常表现为不可逆转的阻塞性肺功能.
- 一些支气管切除症患者表现出支气管扩展剂反应 (BDR),导致支气管扩展剂的使用.
- 在囊性纤维化 (CF) 和其他支气管疾病中评估BDR需要进一步调查.
研究的目的:
- 在患有囊性纤维化 (CF),原发性纤维功能障碍 (PCD) 和非CF/PCD支气管支气管切开症的患者中评估支气管扩展剂反应 (BDR).
- 为了比较这些患者组和健康对照组 (HCs) 之间的BDR.
- 在随机控制的环境中使用不同的计算方法来评估BDR.
主要方法:
- 一项随机对照研究,涉及69名患者 (CF,PCD,非CF/PCD) 和20名HC.
- 参与者接受了萨尔布塔摩尔,其次是安慰剂,或者安慰剂,其次是萨尔布塔摩尔.
- 使用美国胸腔学会 (ATS) /欧洲呼吸学会 (ERS) 标准 (新方法和旧方法) 计算BDR.
主要成果:
- 患有CF和PCD的患者与安慰剂相比,对萨尔布塔摩尔的平均反应在统计学上显著地更大.
- 显著的BDR (新方法,>10%) 是罕见的:CF中0个,PCD中2个,非CF/PCD中0个,HC中2个.
- 旧方法在另外一个PCD患者和三个非CF/PCD患者中发现了BDR.
结论:
- 临床显著的支气管扩展剂反应 (BDR) 在支气管切除症患者中似乎不常见.
- 虽然CF和PCD患者对萨尔布塔摩尔的反应比安慰剂更强,但其临床意义尚不清楚.
- 需要进行进一步的研究,以确定治疗影响和最佳方法,以评估支气管切除症中的BDR.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
319
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
319
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K
Cystic Fibrosis: Management
227
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
227
Antiasthma Drugs: β2-Adrenoceptor Agonists
392
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
392
Drugs Used in Lower Respiratory Disorders: Overview
599
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
599
Chest Physiotherapy
713
Chest Physiotherapy (CPT) is a therapeutic technique used in respiratory care to improve ventilation, clear bronchial secretions, and enhance the efficiency of respiratory muscles. This therapy includes three primary procedures: postural drainage, percussion, and vibration. It can be performed on spontaneously breathing patients and those who are intubated and mechanically ventilated.
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
Purpose
CPT is primarily used for patients with excessive bronchial secretions who have difficulty clearing...
713


